

February 04, 2025

Ref: NIVABUPA/EQ/2024-25/26

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Symbol: NIVABUPA Scrip Code: 544286

Sub: Outcome of Board Meeting held on February 04, 2025
Ref: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform that the Board of Directors of the Company, at its meeting held today i.e. Tuesday, February 04, 2025, inter-alia, have considered and approved the following:

- 1. Un-Audited Standalone Financial Results for the quarter and nine months ended December 31, 2024 along with the Limited Review Report issued by the Joint Statutory Auditors, M/s. S.R. Batliboi & Co. LLP, Chartered Accountants and M/s. T R Chadha & Co. LLP, Chartered Accountants. The copy of Financial results along with Limited Review Report are enclosed herewith as **Annexure-A**;
- Re-appointment of Mr. Krishnan Ramachandran (DIN: 08719264), as Managing Director & CEO of the Company, not liable to retire by rotation, for a period of five years commencing on May 01, 2025 to April 30, 2030, alongwith the terms of re-appointment, subject to approval of the Shareholders and IRDAI. In this regard, the information required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith as Annexure-B.

The Meeting of the Board of Directors commenced at 03:00 P.M. (IST) and concluded at 05:00 P.M. (IST).

Please take the above information on record.

Thanking you,
For Niva Bupa Health Insurance Company Limited

Rajat Sharma Company Secretary & Compliance Officer Membership No. : F7069

S. R. Batliboi & Co. LLP Chartered Accountants

12th Floor, The Ruby, 29 Senapati Bapat Marg Dadar (West), Mumbai- 400 028 Telephone +91 22 6819 8000

TR Chadha & Co. LLP Chartered Accountants

B-30, Kuthiala Building, Connaught Place New Delhi – 110001, India Telephone +91 11 4325 9900

Independent Auditors' Review Report on Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To The Board of Directors, Niva Bupa Health Insurance Company Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of **Niva Bupa Health Insurance Company Limited** (the "Company"), for the quarter and nine months period ended December 31, 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time (the "Listing Regulations") and Insurance Regulatory and Development Authority of India ('IRDAI') circular reference IRDAI/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the requirements of, the recognition and measurement principles laid down in Accounting Standard ("AS") 25, "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, to the extent applicable and are not inconsistent with the accounting principles as prescribed in the Insurance Act, 1938 as amended by the Insurance Laws (Amendment) Act, 2015 (the "Insurance Act"), the Insurance Regulatory and Development Authority Act, 1999 (the "IRDA Act"), Insurance Regulatory and Development Authority of India (Actuarial, Finance and Investment Functions of Insurers) Regulations, 2024 read with Master Circular No. IRDAI/ACTL/CIR/MISC/80/05/2024 dated May 17, 2024 (the "Regulations") and orders/directions/circulars issued by the IRDAI, has not disclosed the information required to be disclosed in accordance with Regulation 33 and Regulation 52 of the Listing Regulations and IRDAI circular reference IRDAI/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017, to the extent applicable, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

4. As discussed in Note 5 to the Statement, the Company is yet to file an application for forbearance for exceeding the Expenses of Management ("EOM") over the allowable limit for financial year 2024-25 with IRDAI. The grant of such forbearance is at IRDAI's discretion and the impact of the same on the Statement will depend on the future development. Our conclusion is not modified in respect of this matter.

S. R. Batliboi & Co. LLP Chartered Accountants

12th Floor, The Ruby, 29 Senapati Bapat Marg Dadar (West), Mumbai- 400 028 Telephone +91 22 6819 8000

TR Chadha & Co. LLP Chartered Accountants

B-30, Kuthiala Building, Connaught Place New Delhi – 110001, India Telephone +91 11 4325 9900

Other Matter

5. The actuarial valuation of liabilities in respect to claims incurred but not reported (IBNR), including claims incurred but not enough reported (IBNER), estimate of loss ratio for determining profit commission on re-insurance treaties, provisioning for premium deficiency and free look reserve as at December 31, 2024 is the responsibility of the Company's Appointed Actuary (the "Actuary") and has been duly certified by the Actuary. The Actuary has also certified that in his opinion, the assumptions for such valuation are in accordance with the guidelines and norms, if any, issued by the IRDAI and the Institute of Actuaries of India in concurrence with the IRDAI. We have relied upon the Actuary's certificate in this regard for forming our conclusion on the accompanying Statement of the Company.

For S. R. Batliboi & Co. LLP Chartered Accountants FRN No. 301003E/E300005

SHRAWAN BHAGWATI JALAN

Digitally signed by SHRAWAN BHAGWATI JALAN DN: cn=SHRAWAN BHAGWATI JALAN, c=IN, o=Personal, email=Shrawan, jalang-srb.in Date: 2025.02.04 17:02:58 +05'30'

per Shrawan Jalan

Partner

Membership No. 102102

UDIN: 25102102BMOBBR7879

Place: Gurugram

Date: February 4, 2025

For T R Chadha & Co. LLP

Chartered Accountants FRN No. 006711N/N500028

NEENA GOEL Digitally signed by NEENA GOEL Date: 2025.02.04 16:51:16 +05'30'

Neena Goel

Partner

Membership No. 057986 UDIN: 25057986BMIKJB1049

Place: Noida

Date: February 4, 2025

CIN: L66000DL2008PLC182918

REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010
Registered Address- C-98, First Floor Lajpat Nagar, Part 1 New Delhi - 110024, India

[Pursuant to the Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with IRDAI Circular reference : IRDA/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017]

Annexure - I
Statement of Unaudited Financial Results for the Quarter and Year to date ended December 31, 2024

(Rs. in Lakhs)

		Thr	ee months ended / As	at I	Year to date of	ended / As at	(Rs. in Lakhs) Year ended / As at
Sr.	.	December 31,	September 30,	December 31,	December 31,	December 31,	March 31,
No.	Particulars	2024	2024	2023	2024	2023	2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
OPER/	ATING RESULTS						
1	Gross Premiums Written	1,44,207	1,77,733	1,41,245	4,68,358	3,84,814	5,60,757
2	Net Premium Written ¹	1,15,243	1,39,329	1,12,017	3,69,732	3,03,903	4,42,095
3	Premium Earned (Net)	1,13,580	1,21,322	94,959	3,36,704	2,59,320	3,81,125
4	Income from Investments (Net) ²	6,791	6,818	4,094	19,357	12,214	16,668
5	Other Income (a) Other Income						
	(b) Contribution from the Shareholders' Account	-	-	-	-	-	
	(i) Towards Excess Expenses of Management	3,632	7,826	4,195	19,837	16,027	21,645
-	(ii) Towards remuneration of MD/CEO/WTD/Other KMPs	3,032	8	39	19,657	77	118
	(iii) Others	-	-	- 39	- 33	- 11	- 110
6	Total income (3 to 5)	1,24,050	1,35,974	1,03,287	3,75,953	2,87,638	4,19,556
	(1 - 1)	.,,,	1,00,011	.,,	2,1.2,222	_,_,,,,,,	.,,
7	Commissions & Brokerage (Net) 3	26,078	28,029	18,745	76,907	49,713	74,818
8	Net commission ³	26,078	28,029	18,745	76,907	49,713	74,818
9	Operating Expenses related to insurance business						
	(a) Employees' remuneration and welfare expenses	15,868	18,939	16,442	52,111	49,606	63,938
	(b) Other operating expenses (i+ii)						
	(i) Advertisement and publicity	2,758	4,586	3,782	11,397	8,361	17,733
<u> </u>	(ii) Other expenses	5,024	4,348	4,560	13,530	14,282	19,045
10	Premium Deficiency	-	-	-	-	-	-
11	Incurred Claims (a) Claims Paid	76,905	66,973	E2 6E0	2.06.040	1 50 000	2 40 620
	(b) Change in Outstanding Claims (including IBNR/IBNER)	(2,924)	7,252	52,650 5,929	2,06,018 7,479	1,50,830 12,721	2,19,628 5,591
12	Total Expense (8+9+10+11)	1,23,709	1,30,127	1,02,108	3,67,442	2,85,513	4,00,753
	Total Expense (013110111)	1,20,700	1,00,121	1,02,100	0,01,442	2,00,010	4,00,700
13	Underwriting Profit / (Loss) (3-12)	(10,129)	(8,805)	(7,149)	(30,738)	(26,193)	(19,628)
14	Provisions for doubtful debts (including bad debts written off)	, ,	- 1	` -		` -	-
15	Provisions for diminution in value of investments	-	-	-	-	-	-
16	Operating Profit/loss: (6-12)	341	5,847	1,179	8,511	2,125	18,803
17	Appropriations						
	(a) Transfer to Profit and Loss Account	341	5,847	1,179	8,511	2,125	18,803
	(b) Transfer to Reserves	-	-	-	-	-	-
	DPERATING RESULTS						
18	Income in shareholders' account (a+b+c)	044	5.047	4.470	0.544	0.405	40.000
	(a) Transfer from Policyholders' Fund	341	5,847 3,988	1,179	8,511	2,125	18,803
	(b) Income from investments (c) Other income	5,431 11	3,966	3,521 783	14,288 107	8,455 953	13,754 315
19	Expenses other than those related to insurance business	4,381	8,531	4,935	21,974	18,830	24,506
20	Provisions for doubtful debts (including bad debts written off)	78	27	90	188	224	181
21	Provisions for diminution in value of investments	-	-	-	-	-	-
22	Total Expense(19+20+21)	4,459	8,558	5,025	22,162	19,054	24,687
	. ,						
23	Profit / (Loss) before extraordinary items (18-22)	1,324	1,302	458	744	(7,521)	8,185
24	Extraordinary Items	-	-	-	-	-	-
25	Profit / (Loss) Before Tax (23-24)	1,324	1,302	458	744	(7,521)	8,185
26	Provision for Tax	-		-		·	
27 28	Profit / (Loss) After Tax (25-26)	1,324	1,302	458	744	(7,521)	8,185
28	Dividend per share (Rs.)						
	(a) Interim Dividends (b) Final dividend	-	-	-	-	-	-
29	(b) Final dividend	- - (92 453)	- - (93 777)	- (1,08,903)	- (92 453)	(1.08 903)	- - (93 197)
29 30		- - (92,453) 1,82,703	- (93,777) 1,71,768	- (1,08,903) 1,69,862	- (92,453) 1,82,703	(1,08,903) 1,69,862	- (93,197) 1,69,954
	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital	- (92,453) 1,82,703 1,04,191	- (93,777) 1,71,768 34,687	- (1,08,903) 1,69,862 19,266	1,82,703		
30 31	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴	1,82,703	1,71,768 34,687	1,69,862 19,266		1,69,862 19,266	1,69,954 35,005
30 31 32	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment	1,82,703 1,04,191	1,71,768 34,687 4	1,69,862 19,266 54	1,82,703 1,04,191	1,69,862 19,266 54	1,69,954 35,005 19
30 31 32 33	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve	1,82,703 1,04,191 - (152)	1,71,768 34,687 4 (0)	1,69,862 19,266 54 (230)	1,82,703 1,04,191 - (152)	1,69,862 19,266 54 (230)	1,69,954 35,005 19 87
30 31 32	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment	1,82,703 1,04,191	1,71,768 34,687 4	1,69,862 19,266 54	1,82,703 1,04,191	1,69,862 19,266 54	1,69,954 35,005 19
30 31 32 33 34	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings	1,82,703 1,04,191 - (152)	1,71,768 34,687 4 (0)	1,69,862 19,266 54 (230)	1,82,703 1,04,191 - (152)	1,69,862 19,266 54 (230)	1,69,954 35,005 19 87
30 31 32 33 34	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund	1,82,703 1,04,191 - (152) 25,000	1,71,768 34,687 4 (0) 25,000	1,69,862 19,266 54 (230) 25,000	1,82,703 1,04,191 - (152) 25,000	1,69,862 19,266 54 (230) 25,000	1,69,954 35,005 19 87 25,000
30 31 32 33 34	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276
30 31 32 33 34	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund	1,82,703 1,04,191 - (152) 25,000	1,71,768 34,687 4 (0) 25,000	1,69,862 19,266 54 (230) 25,000	1,82,703 1,04,191 - (152) 25,000	1,69,862 19,266 54 (230) 25,000	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321	1,69,954 35,005 19 87 25,000
30 31 32 33 34	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331)	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047 (3,65,062)	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331)	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169)	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758)
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (i) Solvency Ratio ^{5a}	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331)	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047 (3,65,062)	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331)	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758)
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (ii) Solvency Ratio ^{5a} (iii) Expenses of Management Ratio ^{5b}	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41.73%	1,71,768 34,687 4 (0) 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,06%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40,50%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2,55 39,31%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (i) Solvency Ratio ^{5a} (ii) Expenses of Management Ratio ^{5b} (iii) Incurred Claim Ratio	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41,73% 65,14%	1,71,768 34,687 4 (0) 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61.18%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,06% 61,69%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40,50% 63,41%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56% 63,07%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39,31% 59,09%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (i) Solvency Ratio ^{5a} (ii) Expenses of Management Ratio ^{5b} (iii) Incurred Claim Ratio (iv) Net retention ratio	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41,73% 65,14% 79,92%	1,71,768 34,687 4 (0) 25,000 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61,18% 78,39%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,06% 61,69% 79,31%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40.50% 63,41% 78,94%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56% 63,07% 78,97%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39,31% 59,09% 78,84%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (i) Solvency Ratio ^{5a} (ii) Expenses of Management Ratio ^{5b} (iii) Incurred Claim Ratio (iv) Net retention ratio (v) Combined ratio	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41,73% 65,14%	1,71,768 34,687 4 (0) 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61.18%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,06% 61,69%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40,50% 63,41%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56% 63,07%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39,31% 59,09% 78,84%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) ⁴ Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios ⁵ (ii) Solvency Ratio ^{5a} (iii) Expenses of Management Ratio ^{5b} (iii) Incurred Claim Ratio (iv) Net retention ratio (v) Combined ratio (vi) Earning per share (Rs.)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41,73% 65,14% 79,92% 108,29%	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61,18% 78,39% 101,30%	1,69,862 19,266 54 (230) 25,000 2,85,321 (3,09,169) 2,56 39,06% 61,69% 79,31% 100,55%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40,50% 63,41% 78,94% 105,04%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56% 63,07% 78,97% 103,20%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39,31% 59,09% 78,84% 98,80%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios 5 (ii) Solvency Ratio 5 (iii) Expenses of Management Ratio 5 (iii) Incurred Claim Ratio (iv) Net retention ratio (v) Combined ratio (v) Combined ratio (v) Earning per share (Rs.) (a) Basic and diluted EPS before extraordinary items (net of tax expense)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41.73% 65.14% 79,92% 108.29%	1,71,768 34,687 4 (0) 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61,18% 78,39% 101,30% Basic: 0.08	1,69,862 19,266 54 (230) 25,000 2,85,321 (3,09,169) 2,56 39,06% 61,69% 79,31% 100,55% Basic: 0.03	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40.50% 63.41% 78.94% 105.04% Basic: 0.04	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2.56 39.56% 63.07% 78.97% 103.20% Basic: (0.48)	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39.31% 59.09% 78.84% 98.80%
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: Shareholders' Fund Policyholders' Fund Ob) Other Assets (Net of current liabilites and provisions) Analytical Ratios (ii) Solvency Ratio (iii) Expenses of Management Ratio (iv) Net retention ratio (v) Combined ratio (vi) Combined ratio (vi) Caming per share (Rs.) (a) Basic and diluted EPS before extraordinary items (net of tax expense) for the period (iii)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41,73% 65,14% 79,92% 108,29%	1,71,768 34,687 4 (0) 25,000 2,5000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61,18% 78,39% 101,30%	1,69,862 19,266 54 (230) 25,000 2,85,321 (3,09,169) 2,56 39,06% 61,69% 79,31% 100,55%	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40,50% 63,41% 78,94% 105,04%	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2,56 39,56% 63,07% 78,97% 103,20%	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39.31% 59.09% 78.84% 98.80% Basic: 0.51 Diluted: 0.50
30 31 32 33 34 35	(b) Final dividend Profit / (Loss) carried to Balance Sheet Paid up Equity Capital Reserve & Surplus (Excluding Revaluation Reserve) Share Application Money Pending Allotment Fair Value Change Account and Revaluation Reserve Borrowings Total Assets: (a) Investments: - Shareholders' Fund - Policyholders' Fund (b) Other Assets (Net of current liabilites and provisions) Analytical Ratios 5 (ii) Solvency Ratio 5 (iii) Expenses of Management Ratio 5 (iii) Incurred Claim Ratio (iv) Net retention ratio (v) Combined ratio (v) Combined ratio (v) Earning per share (Rs.) (a) Basic and diluted EPS before extraordinary items (net of tax expense)	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 41.73% 65.14% 79,92% 108.29%	1,71,768 34,687 4 (0) 25,000 2,56,474 3,40,047 (3,65,062) 2,25 39,41% 61,18% 78,39% 101,30% Basic: 0.08	1,69,862 19,266 54 (230) 25,000 2,85,321 (3,09,169) 2,56 39,06% 61,69% 79,31% 100,55% Basic: 0.03	1,82,703 1,04,191 - (152) 25,000 3,35,346 3,95,727 (4,19,331) 3.03 40.50% 63.41% 78.94% 105.04% Basic: 0.04	1,69,862 19,266 54 (230) 25,000 2,37,800 2,85,321 (3,09,169) 2.56 39.56% 63.07% 78.97% 103.20% Basic: (0.48)	1,69,954 35,005 19 87 25,000 2,58,547 2,87,276 (3,15,758) 2.55 39.31% 59.09% 78.84% 98.80%

CIN: L66000DL2008PLC182918

REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010 Registered Address- C-98, First Floor Lajpat Nagar, Part 1 New Delhi - 110024, India

[Pursuant to the Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with IRDAI Circular reference: IRDA/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017]

Annexure - I

Statement of Unaudited Financial Results for the Quarter and Year to date ended December 31, 2024

(Rs. in Lakhs)

		Three months ended / As at			Year to date ended / As at		Year ended / As at
Sr.	Particulars	December 31,	September 30,	December 31,	December 31,	December 31,	March 31,
No.	i articulars	2024	2024	2023	2024	2023	2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(vii) NPA ratios:						
	a) Gross and Net NPAs	Gross : Rs. 6,324	Gross : Rs. 6,324	Gross : Rs. 6,324	Gross : Rs. 6,324	Gross : Rs. 6,324	Gross : Rs. 6,324
	a) Gloss and Net NEAS	Net : Rs. 0	Net : Rs. 0	Net : Rs. 0	Net : Rs. 0	Net : Rs. 0	Net : Rs. 0
	b) % of Gross & Net NPAs ^{5d}	Gross: 0.86%	Gross: 1.05%	Gross: 1.19%	Gross: 0.86%	Gross: 1.19%	Gross: 1.15%
	D) % Of Gross & Net NPAs	Net : 0%	Net : 0%	Net : 0%	Net : 0%	Net : 0%	Net : 0%
	(viii) Yield on Investments ^{5e}						
	(a) Without unrealized gains	1.84%	1.86%	1.63%	5.27%	4.81%	6.89%
	(b) With unrealised gains	1.70%	2.92%	1.65%	6.09%	5.23%	8.18%
	(ix) Public shareholding						
	a) No. of shares	80,43,35,928	NA	NA	80,43,35,928	NA	NA
	b) Percentage of shareholding	44.02%	NA	NA	44.02%	NA	NA
	c) % of Government holding	NA	NA	NA	NA	NA	NA
	(in case of public sector insurance companies)						

Notes:

- Net of reinsurance (including excess of loss reinsurance).
- 2 Net of amortisation and losses (including capital gains).
- Commission is net of commission received on reinsurance cession. Net of debit balance in Profit & Loss Account.
- 4
- 5 Analytical ratios have been calculated as per definition given in IRDAI analytical ratios disclosures.
- The Solvency has been computed at the last day of the period. 5a
- The Expenses of Management has been computed on the basis of Gross Direct Premium.
- Figures for the three months ended and year to date ended are not annualised.
- 5d
- a) % of Gross NPA = Gross NPA / Total Investments.
 b) % of Net NPA = (Gross NPA Provision on investments) / (Total Investments Provision on investments).
 Yield on investment is computed on average of Opening & Closing Investment.

Annexure - II

[Pursuant to the Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with IRDAI Circular reference:
IRDA/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017]
Segment Reporting for the Quarter and Year to date ended December 31, 2024

(Rs. in Lakhs)

Segment Income:			Three months ended / As at		at	Year to date	Year ended / As at	
Segment Income:	Sr. No.	Particulars						March 31, 2024
AF Fire			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Earned Premium	1	Segment Income:						
Income from Investments		(A) Fire						
Other Income (9) Marine Net Earned Premin		Net Earned Premium	-	•	-	•	•	-
B) Marine		Income from Investments	-	•	-	•	•	-
Net Earned Premium		Other Income	-	•	-	•	•	-
Income from Investments		(B) Marine						
Other Income		Net Earned Premium	-	•	-		•	
C) Total Health		Income from Investments	-	•	-	•	•	-
(i) Health Nel Earned Premium 1.11.263 Nel Earned Premium 1.12.27 Nel		Other Income	-	•	-		•	•
Net Earned Premium		(C) Total Health						
Income from Investments 6.649 6.653 4.003 18.915 11.973		(i) Health						
Other Income 3,802 7,644 4,140 19,437 15,786 (ii) Personal Accident		Net Earned Premium	1,11,263	1,18,776	93,010	3,29,763	2,53,961	3,73,285
(II) Personal Accident		Income from Investments	6,649	6,653	4,003	18,915	11,973	16,332
Net Earned Premium		Other Income	3,602	7,644	4,140	19,437	15,786	21,324
Income from Investments 126		(ii) Personal Accident						
Other Income 68 168 75 391 262		Net Earned Premium	2,044	2,389	1,702	6,317	4,915	7,118
Net Earned Premium		Income from Investments	126	146	72	380	199	275
Net Earned Premium		Other Income	68	168	75	391	262	360
Income from Investments		(iii) Travel						
Other Income		Net Earned Premium	273	157	247	624	444	722
D) Miscellaneous Retail		Income from Investments	16	19	19	62	42	61
(i) Miscellaneous Retail Net Earned Premium		Other Income	9	22	19	64	56	79
Net Earned Premium		(D) Miscellaneous						
Income from Investments		(i) Miscellaneous Retail						
Other Income		Net Earned Premium	-	-	-		-	-
(ii) Miscellaneous Group, Corporate Net Earned Premium		Income from Investments	-	-	-	-	-	-
Net Earned Premium		Other Income	-	-	-	-	-	-
Income from Investments		(ii) Miscellaneous Group, Corporate						
Other Income		Net Earned Premium	-	-	-	-	-	-
E Crop Insurance		Income from Investments	-	-	-	-	-	-
Net Earned Premium		Other Income	-	-	-	-	-	-
Net Earned Premium		(E) Crop Insurance						
Other Income - <t< td=""><td></td><td></td><td>-</td><td>-</td><td>-</td><td></td><td>-</td><td>-</td></t<>			-	-	-		-	-
F) Motor Net Earned Premium		Income from Investments	-		-		-	-
Net Earned Premium		Other Income	-		-		-	-
Income from Investments		(F) Motor						
Other Income - <t< td=""><td></td><td>Net Earned Premium</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></t<>		Net Earned Premium	-	-	-	-	-	-
CG Unallocated Net Earned Premium		Income from Investments	-	-	-	-	-	-
Net Earned Premium -		Other Income	-	-	-	-	-	-
Income from Investments		(G) Unallocated						
Income from Investments		Net Earned Premium	-	-	-	-	-	-
Premium Deficiency:			-		-		-	-
(A) Fire - - - - - (B) Marine - - - - - (C) Total Health - - - - - - (i) Health - <		Other Income	-		-		-	-
(A) Fire -<	2	Premium Deficiency :						
(B) Marine			-	-	-	-	-	-
(C) Total Health -			-	-	-	-	-	-
(i) Health (ii) Personal Accident (iii) Travel (D) Miscellaneous Retail								
(ii) Personal Accident - - - - - (iii) Travel - - - - - (D) Miscellaneous (i) Miscellaneous Retail - - - - - (ii) Miscellaneous Group, Corporate - - - - - -			-	-	-	-	-	-
(iii) Travel - - - - - (D) Miscellaneous (i) Miscellaneous Retail - - - - - - (ii) Miscellaneous Group, Corporate - - - - - - -			-	-	-	-	-	-
(D) Miscellaneous -			-	-	-	-	-	_
(i) Miscellaneous Retail - - - - - (ii) Miscellaneous Group, Corporate - - - - -								
(ii) Miscellaneous Group, Corporate		· /	_	-	_	-	-	-
					_	-		-
		(E) Crop Insurance			_	-	-	-
(F) Motor					_	-	-	-
(G) Unallocated				-	_	-	-	-

Annexure - II

[Pursuant to the Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with IRDAI Circular reference : IRDA/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017]

Segment Reporting for the Quarter and Year to date ended December 31, 2024

(Rs. in Lakhs)

	Particulars	Thre	ee months ended / As	at	Year to date e	Year ended / As at	
Sr. No.		December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
3	Segment Underwriting Profit / (Loss):						
	(A) Fire	-	-	-	-	-	
	(B) Marine	-	-	-	-	-	
	(C) Total Health						
	(i) Health	(10,102)	(8,588)	(7,480)	(29,917)	(26,829)	(21,804
	(ii) Personal Accident	3	117	208	303	548	2,187
	(iii) Travel	(30)	(334)	123	(1,124)	88	(11
	(D) Miscellaneous						
	(i) Miscellaneous Retail	-	-	-	-	-	
	(ii) Miscellaneous Group, Corporate	-	-	-	-	-	
	(E) Crop Insurance	-	-	-	-	-	
	(F) Motor	-	-	-	-	-	
	(G) Unallocated	-	-	-	-	-	
4	Segment Operating Profit / (Loss):						
	(A) Fire	-	-	-	-	-	
	(B) Marine	-	-	-	-	-	
	(C) Total Health						
	(i) Health	149	5,709	663	8,435	930	15,852
	(ii) Personal Accident	197	431	355	1,074	1,009	2,82
	(iii) Travel	(5)	(293)	161	(998)	186	129
	(D) Miscellaneous	(=)	(===)		(***)		
	(i) Miscellaneous Retail	_	_	_	-	_	
	(ii) Miscellaneous Group, Corporate	_	-	_	_		
	(E) Crop Insurance	_	-	_	_		
	(F) Motor	_ 1	_	_	_	_	
	(G) Unallocated	_	_	_	_	_	
5	Segment Technical Liabilities:						
•	Unexpired Risk Reserve - Net						
	(A) Fire	_	_	_	_	_	
	(B) Marine	_	_	_			
	(C) Total Health						
	(i) Health	2,48,563	2,46,891	2,00,921	2,48,563	2,00,921	2,16,896
	(ii) Personal Accident	5,083	4,940	3,437	5,083	3,437	3,645
	(iii) Travel	515	667	388	515	388	592
	(D) Miscellaneous	313	007	300	313	300	39.
	(i) Miscellaneous Retail	_	_	_	_	_	
	(ii) Miscellaneous Group, Corporate	-	-	-	_		
	(E) Crop Insurance	_	_	_			
	(F) Motor	_	_	_			
	(G) Unallocated	-	-	-	_		
	Outstanding Claims Reserves including IBNR & IBNER - Net	-	-	-	-		
	(A) Fire	-	-	-	-	-	
	(B) Marine	-	-	-	-	-	
	(C) Total Health						
	(i) Health	46,801	49,438	46,535	46,801	46,535	39,799
	(ii) Personal Accident	1,830	1,750	1,998	1,830	1,998	1,65
	(iii) Travel	423	790	173	423	173	12
	(D) Miscellaneous						
	(i) Miscellaneous Retail	-	-	-	-	-	
	(ii) Miscellaneous Group, Corporate	-	-	-	-	-	
	(E) Crop Insurance	-	-	-	-	-	
	(F) Motor	-	-	-	-	_	
	(G) Unallocated	_	_	_	_	_	

Footnotes:

- 1 Segments include: (A) Fire, (B) Marine, (C) Total Health (i) Health, (ii) Personal Accident, and (iii) Travel, (D) Miscellaneous (i) Retail, (ii) Group, Corporate, (E) Crop Insurance, (F) Motor.
- 2 Income from Investment and Other Income which cannot be allocated to any segment are apportioned on the basis of Gross Direct Premium.
- 3 This annexure is prepared as per the IRDAI segment.

CIN: L66000DL2008PLC182918

REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010 Registered Address- C-98, First Floor Lajpat Nagar, Part 1 New Delhi - 110024, India

[Pursuant to the Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with IRDAI Circular reference: IRDA/F&A/CIR/LFTD/027/01/2017 dated January 30, 2017]

Other Disclosures* Status of Shareholders Complaints for the quarter ended December 31, 2024

Sr. No.	Particulars	Number
1	No. of Investors complaints pending at the beginning of the period	-
2	No. of Investors complaints received during the period	269
3	No. of Investors complaints disposed off during the period	264
4	No. of Investors complaints remained unresolved at the end of the period	5

Company had received 269 complaints during the quarter ended December 31, 2024, including 15 complaints received on SEBI Scores portal. Being the first quarter after listing, all these complaints mainly pertain to non-receipt of refund of IPO Application by Investors (Resident Individuals). Out of 269 complaints, 264 complaints were attended and disposed-off within the quarter. As on December 31, 2024, 5 complaints remain unresolved.

^{*} The above disclosure is not required to be audited

Notes forming part of Financial Results

- 1 The above financial results for the quarter & year to date ended December 31, 2024 have been reviewed by the Audit Committee in their meeting held on February 04, 2025 and are approved by the Board of Directors in their meeting held on February 04, 2025 and such results were reviewed by the joint statutory auditors, S.R. Batliboi & Co. LLP, Chartered Accountants and T R Chadha & Co. LLP, Chartered Accountants, who have issued an unmodified conclusion on these financial results.
- 2 The company has completed Initial Public Offer (IPO) of equity shares of face value Rs.10 each at an issue price of Rs.74 per equity share, comprising of fresh issue of 10,81,08,108 shares and offer for sale of 18,91,89,188 shares by 'selling share holders'. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on November 14, 2024.

The details of IPO Proceeds (fresh issue) of Rs. 80,000 lakhs are as follows:

Objects of the issue	IPO Proceeds	Funds Utilized as at December 31, 2024	Funds Unutilized as at December 31, 2024
Augmentation of capital base to maintain and strengthen solvency levels	80,000 lakhs	77,847 lakhs	2,153 lakhs

During the year to date ended December 31, 2024, the Company has allotted 1,93,83,695 equity shares pursuant to exercise of employee stock options granted.

- 3 The provisions of Section 71 of the Companies Act, 2013 read with Rule 18 of the Companies (Share Capital and Debentures) Amendment Rules, 2014 are applicable to the Company. However, as per Rule 18, Debenture Redemption Reserve shall be created out of profits of the Company available for payment of dividend, since the Company's equity shares are listed as at December 31, 2024 and the Company does not have profits which are available for payment of dividend, hence no Debenture Redemption Reserve is being created.
- 4 Regulation 54(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable as the Company has issued unsecured non-convertible debt securities. In terms of Regulation 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and SEBI Circular No. SEBI/HO/MIRSD/MIRSD_CRADT/CIR/P/2022/67 dated May 19, 2022, the Company has issued 'un-secured' non-convertible debentures, as a result, the requirement of security cover is not applicable on the Company.
- 5 During the quarter ended December 31, 2024, the Company has received the forbearance approval for exceeding the Expenses of Management (EOM) over the allowable limit for FY 2022-23 and FY 2023-24. Further, on the basis of discussions with Insurance Regulatory and Development Authority of India ("IRDAI"), the Company has computed expenses of management ("EOM") in accordance with accounting methodology applied before Master Circular on Actuarial, Finance and Investment Functions of Insurers dated May 17, 2024 read with clarification dated October 18, 2024 issued by IRDAI for multi-year policies and related commissions income and expenses was made applicable. Accordingly, excess EOM amounting to Rs. 3,632 lakhs & Rs. 19,837 lakhs have been transferred from revenue account to profit and loss account for the quarter & year to date ended December 31, 2024 respectively. The Company's EOM ratio for the quarter & year to date ended December 31, 2024 is 37% and 39% respectively.
- 6 The Appointed Actuary has certified to the Company that actuarial estimates for claims incurred but not reported (IBNR) (including claims incurred but not enough reported (IBNER)) reserves have been determined using actuarial principles. In the determination, the Actuarial Practice Standards issued by the Institute of Actuaries of India and any directions issued by the Authority in this behalf have been followed. Where credible data is available, the Actuary has chosen to adopt the Chain Ladder Method. In other cases, expected ultimate loss ratio method or fixed IBNR method have also been used. These IBNR reserves include Margin for Adverse Deviation and reserves for Unallocated Loss Adjustment Expenses (ULAE) for the claims up to December 31, 2024. Net IBNR reserves have been arrived on the basis of actuarial estimates based on the claim data, after allowance for reinsurance recoveries.
- 7 Pursuant to an inquiry by Directorate General of GST Intelligence (DGGI) relating to certain input credit availed by the Company, it has provided all information and clarifications to DGGI. As directed by DGGI authorities, the Company has paid Rs. 2,500 Lakhs under Section 74(5) of the CGST Act 2017. The Company believes, it had taken input credit in accordance with relevant provisions of the statue. The Company had also received summons under Section 131 (1A) from the income tax authorities and has provided all the information and clarifications to them. Pending completion of such inquiry, there is no impact considered on the financial results for the year to date ended December 31, 2024. The Company has received Show Cause Notice from DGGI- Mumbai on Marketing expenses of Rs. 2,929 lakhs. The same has been duly replied on March 26, 2024 and next due date of hearing the same is February 05, 2025. The Company has shown this amount in Contingent Liability.
- 8 In view of the seasonality of Industry, the financial results for the quarters are not indicative of full year's expected performance.
- 9 In accordance with the IRDAI (Actuarial, Finance and Investment Functions of Insurers) Regulation, 2024 and Master circular thereon dated May 17, 2024 and subsequent clarification dated October 18, 2024, with effect from October 1, 2024 the Company has given the effect to recognise gross written premium on a 1/n basis where "n" denotes the policy duration and commission expenses paid and commission income accrued on such recorded gross written premium for applicable long-term products. This has resulted in a decrease in gross written premium by Rs. 32,770 lakhs and net decrease in commission by Rs. 2,621 lakhs, and related effect in operating profit for the quarter and nine months ended December 31, 2024.
- 10 In accordance with IRDAI (Actuarial, Finance and Investment Functions of Insurers) Regulation, 2024 read with Master circular thereon dated May 17, 2024 and further clarification from IRDAI on January 31, 2025, the change in methodology of calculation of admissible assets for reinsurers and co-insurers receivables have no impact in the solvency ratio as at December 31, 2024.
- 11 For the quarter and year to date ended December 31, 2024, out of estimated amount of Rs. 9,527 lakhs, the Company has incurred Rs. 3,640 lakhs as initial public offering ("IPO") related expenses and allocated such expenses between the Company Rs. 1,324 lakhs and selling shareholders Rs. 2,316 lakhs. Such amounts were allocated based on agreement between the Company and 'selling share holders' and in proportion to the total proceeds of the IPO. The Company's share of expenses of Rs. 1,324 lakhs have been adjusted to securities premium. As at December 31, 2024, the Company has not received the invoices of Rs. 5,887 lakhs and hence Company's share of expenses amounting to Rs. 2,153 lakhs have not been adjusted to Securities Premium Account.
- 12 Figures for the quarter ended December 31, 2024 and December 31, 2023 are the balancing figures for year to date figures upto the end of the third quarter of the financial year and published figures of year to date figures upto the end of the second quarter of the financial year.
- 13 The Indian Parliament has approved the Code on Social Security, 2020, which would impact the contributions by the Company towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified and the final rules are yet to be framed. The Company will carry out an evaluation of the impact and record the same in the financial results in the period in which the code becomes effective and related rules are published.
- 14 In accordance with the Insurance Regulatory and Development Authority of India (Actuarial, Finance and Investment Functions of Insurers) Regulations, 2024, previous period figures have been regrouped / reclassified wherever necessary and the effect of that is given in Underwriting balance ratio, Expenses of Management to Gross Direct Premium Ratio, Expense of Management to Net Written Premium Ratio, Operating Profit Ratio and Combined Ratio, while the Profit after tax will remain same.

(Rs. in Lakhs)

	Regrouped from	Regrouped to	Period ended	Amount	
i.	Operating Expenses related to Insurance	Operating Expenses related to Insurance Towards remuneration of	3 months ended December 31, 2023	39	
П	Business [#]	MD/CEO/WTD/Other KMPs under the head	Year to date ended December 31, 2023	77	
Ш		'Other'	Year ended March 31, 2024	118	
# F	Excess of Managerial remuneration over and above limit as prescribed by IRDAL regulation was earlier petted from 'Operating Expenses' related to Insurance Business' is now shown under the head 'Other'				

For better presentation, previous period figures have been regrouped / reclassified wherever necessary and the effect of that is given in Net Incurred Claims to Net Earned Premium Ratio and Combined Ratio, while the Profit after tax will remain same.

(Rs. in Lakhs)

L	Regrouped from	Regrouped to	Period ended	Amount
ii			3 months ended September 30, 2024	40
	Operating Expenses related to Insurance	Operating Expenses related to Insurance Business Claims Incurred (Net)	3 months ended December 31, 2023	64
	Business		Year to date ended December 31, 2023	213
L			Year ended March 31, 2024	265

CIN: L66000DL2008PLC182918

REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010

Registered Address- C-98, First Floor Lajpat Nagar, Part 1 New Delhi - 110024, India [Pursuant to the Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended]

Three months ended / As at Year to date ended / As at Year ended / As at December 31, September 30, December 31. December 31, December 31. March 31. Particulars No. 2024 2024 2023 2024 2023 2024 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Debt-Equity Ratio (No. of times) (Note 1) 0.09 0.12 0.13 0.09 0.13 0.12 Debt Service Coverage Ratio (No. of times) (Note 2) 1.69 1.37 (2.74)4.06 2.96 2.93 3 Interest Service coverage Ratio (No. of times) (Note 3) 2.96 2.93 1.69 1.37 (2.74) 4.06 Outstanding redeemable preference shares (quantity and value) NA NA NA NA NΑ NA NA NA NA NA NA NA 5 Capital redemption reserve/Debenture redemption reserve (Note 4) Net Worth (Rs in Lakhs) 2,86,894 2,06,455 1,89,129 2,86,894 1,89,129 2,04,959 7 Net Profit after tax (Rs in Lakhs) 1,324 1,302 458 (7,521 8,185 8 Earning Per Share -Basic Earning/ (Loss) per Share of Rs. 10/- each 0.07 0.08 0.03 0.04 (0.48) 0.51 -Diluted Earning/ (Loss) per Share of Rs. 10/- each 0.07 0.07 0.03 0.04 (0.48 0.50 9 Current Ratio (Note 5) 0.13 0.13 0.17 0.20 0.23 0.20 10 Long term Debt to Working capital (Note 6) (0.07 (0.08)(0.08) (0.08)(0.06)(0.06)11 Bad Debts to Account Receivable ratio (Note 10) NA NA NA NA NA NA Current liability Ratio (Note 7) 12 0.96 0.95 0.94 0.96 0.94 0.94 13 Total Debts to Total Assets (Note 8) 0.03 0.03 0.04 0.03 0.04 0.04 14 Debtors turnover (Note 10) NA NA NA NA NA NA 15 Inventory turnover (Note 10) NA NA NA NA NA NA 16 Operating Margin (Note 10) NA NA NA NA NA NA 17 Net Profit Margin (Note 10) NA NA NA NA NA NA Sector Specific Relevant Ratios 18 Operating Profit Ratio 4.82% 1.24% 2.53% 0.82% 4.93% 0.30% 19 Net earning ratio 1.15% 0.93% 0.41% 0.20% (2.47% 1.85% 20 Gross Direct Premium Growth Rate 2.10% 34.99% 42.25% 21.71% 40.51% 37.68% 21 Expense of Management to Net Written Premium Ratio (Note 11) 52 22% 50.27% 49 25% 51 31% 50 10% 49 86% 22 Underwriting balance ratio (No. of times) (0.09 (0.07 (0.07 (0.09) (0.10) (0.05) 23 Net Commission Ratio 22.63% 20.129 16.73% 20.80% 16.369 16.929 24 Liquid Assets to liabilities ratio (No. of times) 0.15 0.20 0.20 0.18 0.28 0.28 25 Gross Direct Premium to Net worth Ratio (No. of times) 0.50 0.86 0.7 2.03 2.74 1.63 26 Technical Reserves to net premium ratio (No. of times) 2.63 2.19 2.26 0.82 0.83 0.59 27 Growth rate of Net Worth 51.69% 90.199 139.10% 51.69% 139.109 146.60% Return on net worth ratio 0.46% 0.63% 0.24% 0.26% (3.98% 3.99% 28 29 Claims paid to Claims provision 88.00% 87.00% 87.00% 82.009 87.00% 87.009 30 Net Retention Ratio 79.92% 78.399 79.319 78.94% 78.979 78.84% 31 Expense of Management to Gross Direct Premium Ratio (Note 11) 41.73% 39.419 39.069 40.50% 39.569 39.319 32 Net Incurred Claims to Net Earned Premium 65.14% 61.69% 63.41% 61.189 63.079 59.09% 33 Combined Ratio 108.29% 100.55% 105.04% 103.209 98.80% 101.30% 34 Investment income ratio 1.84% 1.649 5.27% 6.90% 1.869 4.81% 35 Available Solvency margin Ratio to Required Solvency Margin Ratio (No. of times) 3.03 2.25 2.56 3.03 2.56 2.55 36 NPA Ratio (Note 9) -Gross NPA Ratio 0.86% 0.86% 1.15% 1.05% 1.19% 1.19% -Net NPA Ratio 0% 0% 0% 0% 0% 0% 37 Security Cover Ratio (Note 12) NA NA NA NA NA NA 38 Book value per share 15.70 11.13 15.70 11.13 12.06

Notes:

- 1 Debt Equity Ratio is calculated as Total Borrowings divided by Net worth.
- 2 Debt-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense together with principal repayments of long term debt made during the period.
- 3 Interest-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense of long term debt.
- 4 The provisions of Section 71 of the Companies Act, 2013 read with Rule 18 of the Companies (Share Capital and Debentures) Amendment Rules, 2014 are applicable to the Company. However, as per Rule 18, Debenture Redemption Reserve shall be created out of profits of the Company available for payment of dividend, since the Company's equity shares are listed as at December 31, 2024 and the Company does not have profits which are available for payment of dividend hence, no Debenture Redemption Reserve is being created.
- 5 Current Ratio is current assets (cash and bank Balance and advances & other assets) divided by current liabilities and provisions.
- 6 Long term debt to working capital is computed as Long term debt divided by the working capital (working capital= current asset-current liabilities and provisions).
- 7 Current Liability Ratio is computed as 'current liabilities and provision' divided by total liabilities. Total liability includes borrowings, current liabilities and provisions
- 8 Total Debts to Total Assets is total borrowings divided by total assets (excluding fair value change) as per balance sheet.
- 9 Gross/Net NPA ratios pertains to Non -Performing Investments.
- 10 Not Applicable to Insurance Companies.
- 11 Expense of Management has been computed on basis of gross direct commission and operating Expenses.
- 12 The Security Cover is not applicable since the Company does not have any secured listed non-convertible securities.
- 13 Figures for the three months ended and year to date ended are not annualised.

For on and Behalf of Board of Directors

RAMACHANDR AN KRISHNAN

Digitally signed by RAMACHANDRAN KRISHNAN Date: 2025.02.04 16:40:00 +05'30'

Krishnan Ramachandran Managing Director & CEO DIN: 08719264

Place : Gurugram Date: February 04, 2025



Annexure-B

Information as required under Regulation 30 and Schedule III of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Reason for Change	Re-appointment
Date of Appointment and	May 01, 2025
term of appointment /reappointment	For a period of five years commencing on May 01, 2025 to April 30, 2030, subject to approval of the Shareholders and IRDAI.
Brief Profile	Mr. Krishnan Ramachandran holds a Bachelor's of Technology degree in Electrical and Electronic Engineering from Indian Institute of Technology - Madras, Tamil Nadu and holds a Post-Graduate Diploma in Management from Indian Institute of Management, Calcutta, West Bengal. He has been associated with the Company since April 2020. He has over 24 years of experience across health insurance, healthcare & life sciences industries. Previously, he has been associated with Apollo Munich Health Insurance Company Limited as their Chief Executive Officer and had been a consultant with Deloitte Consulting L.P. and Arthur Andersen. He had also been associated with Apollo DKV Insurance Company Ltd. as their Chief Operating Officer in 2007.
Disclosure of relationships between directors	None
Information as required under BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018	Mr. Krishnan Ramachandran is not debarred from holding office of Managing Director, by virtue of any SEBI order or any other authorities as required under the circular issued by the Stock Exchange(s).